Compared with oral ADs, early intensive insulin therapy in patients with newly diagnosed T2D is associated with a favorable impact on recovery and maintenance of β-cell function, as well as prolonged glycemic remission. This evidence concerns the gene INS and type 2 diabetes mellitus.